Last reviewed · How we verify
Placebo Device & Nasacort
Placebo Device & Nasacort is a Corticosteroid Small molecule drug developed by Clayton Sleep Insititute. It is currently in Phase 3 development for Seasonal allergic rhinitis, Perennial allergic rhinitis.
Nasacort is a corticosteroid that works by reducing inflammation in the nasal passages.
Nasacort is a corticosteroid that works by reducing inflammation in the nasal passages. Used for Seasonal allergic rhinitis, Perennial allergic rhinitis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo Device & Nasacort |
|---|---|
| Sponsor | Clayton Sleep Insititute |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
It does this by inhibiting the release of inflammatory mediators from mast cells and other cells in the nasal mucosa, leading to a decrease in symptoms of allergic rhinitis.
Approved indications
- Seasonal allergic rhinitis
- Perennial allergic rhinitis
Common side effects
- Nasal congestion
- Headache
- Nausea
- Dizziness
Key clinical trials
- Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study (NA)
- Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (PHASE3)
- Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Device & Nasacort CI brief — competitive landscape report
- Placebo Device & Nasacort updates RSS · CI watch RSS
- Clayton Sleep Insititute portfolio CI
Frequently asked questions about Placebo Device & Nasacort
What is Placebo Device & Nasacort?
How does Placebo Device & Nasacort work?
What is Placebo Device & Nasacort used for?
Who makes Placebo Device & Nasacort?
What drug class is Placebo Device & Nasacort in?
What development phase is Placebo Device & Nasacort in?
What are the side effects of Placebo Device & Nasacort?
Related
- Drug class: All Corticosteroid drugs
- Manufacturer: Clayton Sleep Insititute — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Seasonal allergic rhinitis
- Indication: Drugs for Perennial allergic rhinitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing